Open Access Highly Accessed Case report

Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields

Aaron Michael Rulseh1, Jiří Keller12, Jan Klener3, Jan Šroubek3, Vladimír Dbalý3, Martin Syrůček4, František Tovaryš3 and Josef Vymazal15*

Author Affiliations

1 Department of Radiology, Na Homolce Hospital, Prague, Czech Republic

2 Charles University in Prague, 3rd Medical Faculty, Prague, Czech Republic

3 Department of Neurosurgery, Na Homolce Hospital, Prague, Czech Republic

4 Department of Pathology, Na Homolce Hospital, Prague, Czech Republic

5 Department of Neurology, Charles University in Prague, 1st Medical Faculty, Prague, Czech Republic

For all author emails, please log on.

World Journal of Surgical Oncology 2012, 10:220  doi:10.1186/1477-7819-10-220

Published: 24 October 2012


Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor, and has a median survival of only 10 to 14 months with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median survival to only five to seven months with optimal therapy. Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency electric fields (100 to 300 kHz) may induce apoptosis in specific cell types. Our center was the first to apply TTField treatment to histologically proven GBM in a small pilot study of 20 individuals in 2004 and 2005, and four of those original 20 patients are still alive today. We report two cases of GBM and two cases of RGBM treated by TTField therapy, all in good health and no longer receiving any treatment more than seven years after initiating TTField therapy, with no clinical or radiological evidence of recurrence.

Glioblastoma multiforme; Recurrent glioblastoma multiforme; Tumor-treating fields; Long-term survival